These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 4374357)

  • 1. Comparative toxicity on leukocytes and platelets of two regimens of CCNU: the relationship between maximum dose and optimum dose.
    Israel L; Chahinian P
    Eur J Cancer (1965); 1973; 9(11-12):799-802. PubMed ID: 4374357
    [No Abstract]   [Full Text] [Related]  

  • 2. Growth curve modification of measurable tumors by 75 mg/m2 of CCNU every 3 weeks.
    Israel L; Chahinian P; Accard JL; Choffel C; Combes PF; Danrigal A; Germouty J; Migueres J; Schaerer R; Sotto JJ
    Eur J Cancer (1965); 1973; 9(11-12):789-97. PubMed ID: 4804306
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of a nitrosourea (CCNU, NSC-79037) in advanced nonhematologic cancer.
    Perloff M; Muggia FM; Ackerman C
    Cancer Chemother Rep; 1974; 58(3):421-4. PubMed ID: 4841718
    [No Abstract]   [Full Text] [Related]  

  • 4. Preliminary clinical trial of 1-(2-chlorethyl)-3-(4-methylcyclohexyl)-1 nitrosourea (NSC-95411) (MeCCNU) in human neoplasms.
    Gailani S; Kutcher J
    J Med; 1973; 4(4):209-18. PubMed ID: 4520348
    [No Abstract]   [Full Text] [Related]  

  • 5. Trial of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in advanced bronchogenic carcinoma 1,2,3.
    Stolinsky DC; Bull FE; Pajak TF; Bateman JR
    Oncology; 1975; 31(5-6):288-92. PubMed ID: 174040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of CCNU (NSC-79037) in the treatment of advanced gastrointestinal cancer.
    Klaassen DJ; Rapp E
    Cancer Chemother Rep; 1974; 58(5 Pt 1):667-9. PubMed ID: 4426046
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II study of the effect of methyl-CCNU (NSC-95441) on bronchogenic carcinoma.
    Takita H; Brugarolas A; Mittelman A; Vincent R
    Cancer Chemother Rep 3; 1973 Mar; 4(2):257-9. PubMed ID: 4125743
    [No Abstract]   [Full Text] [Related]  

  • 8. A combination of adriamycin, CCNU and hydroxyurea in the treatment of disseminated bronchogenic carcinoma.
    Alberto P; Barrelet L; Chapuis B; Garcia B
    Eur J Cancer (1965); 1975 Nov; 11(11):795-9. PubMed ID: 767111
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of CCNU (NSC-79037) on bronchogenic carcinoma.
    Takita H; Brugarolas A
    J Natl Cancer Inst; 1973 Jan; 50(1):49-53. PubMed ID: 4348225
    [No Abstract]   [Full Text] [Related]  

  • 10. Lomustine treatment of metastatic renal cell carcinoma.
    Mittelman A; Albert DJ; Murphy GP
    JAMA; 1973 Jul; 225(1):32-5. PubMed ID: 4740302
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of malignant melanoma with methyl CCNU.
    Young RC; Canellos GP; Chabner BA; Schein PS; Brereton HD; DeVita VT
    Clin Pharmacol Ther; 1974 Jun; 15(6):617-22. PubMed ID: 4601745
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination chemotherapy with adriamycin (NSC-123127) and 1-(2-chloroethyl)-3-cyclohexyl 1-nitrosourea (CCNU; NSC-79037).
    Einhorn LH; Livingston RB; Gottlieb JA
    Cancer Chemother Rep; 1973; 57(4):437-45. PubMed ID: 4586951
    [No Abstract]   [Full Text] [Related]  

  • 13. Initial clinical trials with methyl-CCNU 1-(2-chlorethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU).
    Young RC; Walker MD; Canellos GP; Schein PS; Chabner BA; DeVita VT
    Cancer; 1973 May; 31(5):1164-9. PubMed ID: 4705154
    [No Abstract]   [Full Text] [Related]  

  • 14. Proceedings: Superiority of adriamycin over oral nitrosoureas in patients with advanced breast carcinoma. A Southwest Cancer Chemotherapy study Group study.
    Gottlieb JA; Rivkin SE; Spigel SC; Hoogstraten B; O'Bryan RM; Delaney FC; Singhakowinta A
    Cancer; 1974 Feb; 33(2):519-26. PubMed ID: 4812769
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of 5-azacytidine (NSC-102816) with CCNU (NSC-79037) in the treatment of patients with breast cancer and evaluation of the subsequent use of cyclophosphamide (NSC-26271).
    Cunningham TJ; Nemoto T; Rosner D; Knight E; Taylor S; Rosenbaum C; Horton J; Dao T
    Cancer Chemother Rep; 1974; 58(5 Pt 1):677-81. PubMed ID: 4138966
    [No Abstract]   [Full Text] [Related]  

  • 16. A phase II study of methyl CCNU in the treatment of solid tumors and lymphomas: a Southwest Oncology Group study.
    Tranum BL; Haut A; Rivkin S; Weber E; Quagliana JM; Shaw M; Tucker WG; Smith FE; Samson M; Gottlieb J
    Cancer; 1975 Apr; 35(4):1148-53. PubMed ID: 1116106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCNU-adriamycin therapy in bronchogenic carcinoma.
    Trowbridge RC; Kennedy BJ; Vosika GJ
    Cancer; 1978 May; 41(5):1704-9. PubMed ID: 206337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy for bronchogenic carcinoma. Methotrexate, doxorubicin, cyclophosphamide, and lomustine.
    Chahinian PA; Arnold DJ; Cohen JM; Purpora DP; Jaffrey IS; Teirstein AS; Kirschner PA; Holland JF
    JAMA; 1977 May; 237(22):2392-6. PubMed ID: 576939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of methyl-CCNU(NSC-95441) in the treatment of lung cancer.
    Richards F; Pajak TF; Cooper MR; Spurr CL
    Cancer Chemother Rep; 1973; 57(4):419-22. PubMed ID: 4357670
    [No Abstract]   [Full Text] [Related]  

  • 20. Combination chemotherapy of bronchogenic carcinoma with cyclophosphamide (NSC-26271) and BCNU (NSC-409962).
    Curtis JE
    Cancer Chemother Rep; 1974; 58(6):883-8. PubMed ID: 4614897
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.